间充质干细胞在1型糖尿病胰岛移植中的应用进展

Application progress of mesenchymal stem cells in islet transplantation for type 1 diabetes mellitus

胰岛移植被认为是治疗1型糖尿病的有效方法之一,但其疗效受到多种因素限制。胰岛在分离、培养和移植过程中的缺氧、应激及排斥反应,都会影响胰岛移植的结局。间充质干细胞(MSC)因其抗炎、促进血管生成和调节免疫代谢等生物特性,一直备受研究者关注。此外,MSC的衍生物如外泌体在调节缺氧诱导的氧化应激、促进机体血管形成和调节免疫方面也具有重要作用。基于MSC的胰岛移植可能是1型糖尿病的有效治疗方法。因此,本文就MSC在胰岛移植前后发挥的潜在作用进行综述,并探讨其临床应用及局限性,以期为今后胰岛移植治疗1型糖尿病的相关研究提供新的思路和见解。

Islet transplantation is considered as one of the most effective approach for type 1 diabetes mellitus,although its efficacy is limited by several factors.Anoxia,stress and rejection occurring during the isolation,culturing and transplantation of islets may have impact on the outcome of the islet transplantation.Due to the biological properties such as anti-inflammation,angiogenetic promotion and immune regulation,mesenchymal stem cells(MSCs)are all the way focused by researchers.Additionally,exosome,a derivative of MSC,also plays an import role in regulating anoxiainduced oxidative stress modulation,angiogenetic promotion,and immune regulation.MSC-based islet transplantation may be a useful therapeutic tool in treating type 1 diabetes.Therefore,in this review,the potential effect of MSC prior and posterior to the operation of the islet transplantation,its clinical application as well as its limitations were reviewed,aiming to offer insights into the future application of islet transplantation in treating type 1 diabetes.